A Study to Evaluate Efficacy of Dietary Ingredient in Vitality and Metabolic Factors in Healthy Individuals

Vedic Lifesciences

Status: Completed

Conditions: Aging

Treatments: Dietary Supplement: Placebo (MCC); Dietary Supplement: Dolichos biflorus (Horsegram) seed extract; Dietary Supplement: Carica papaya leaves extract

Study type: Interventional

Funder types: Industry

Identifiers

NCT06188949

EB/231101/DI/VMF

Details and patient eligibility

About

The present study is a randomized, placebo-controlled, feasibility study to evaluate efficacy of dietary ingredients in vitality & metabolic factors in healthy individuals. Approximately 54 subjects aged between ≥ 40 and ≤ 60 years will be screened and 36 participants (12 in each arm) are to be randomized. Both the IP and placebo study arms will have 10 completed subjects in each arm after accounting for the screening failure and dropout/withdrawal rate of 30% and 17% respectively (Total 30 completers). The treatment duration for all the study subjects will be 90 days.

Enrollment: 35 patients

Sex: All

Ages: 40 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Physically active males and females aged ≥40 and ≤ 60 years

• Individuals with BMI ≥ 24.5 kg/m2 and ≤ 34.9 kg/m2

• Individuals with Fatigue Symptom Severity score ≥36 and ≤45

• Individuals with Perceived Stress score ≥20

• Having at least 2 of the following five metabolic risk factors:

  1. Waist circumference: Men: ≥ 102 cm (40.15 inches); Women ≥88 cm (34.65 inches)
  2. Triglycerides >150 mg/dL
  3. Systolic Blood pressure (SBP) ≥130 mm Hg and/or Diastolic Blood pressure (DBP) ≥85 mm Hg
  4. Fasting blood glucose ≥ 125 mg/ dl
  5. HDL level: Men: < 40 mg/dL; Women: < 50 mg/dL

• Individuals willing to provide signed Consent

Exclusion criteria

• Individuals on strict vegetarian diet.
• Individuals with fasting blood sugar ≥160 mg/dl
• Individuals currently hospitalized or planned for admission Individuals
• Individuals currently undergoing treatment with any other drugs such as insulin, corticoids, and non-steroidal anti-inflammatory drugs for more than 15 days.
• Individuals undergoing treatment of chemotherapy and/or suffering from AIDS, hepatitis, pregnancy are precluded from the study.
• Individuals undergoing chemotherapy
• Individuals suffering from AIDS, hepatitis.
• Individuals allergic to components of this nutraceutical formulations.
• Use of medications in the last 2 weeks prior to the pre-baseline period. This does not include birth control pills or standard multi-vitamin/mineral supplements.
• Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening.
• Abnormal Thyroid Stimulating Hormone (TSH) value which is < 0.40 or > 4.50 μIU/mL.
• Diagnosed cases of Type II Diabetes Mellitus with medication
• Hypertensive defined as SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg
• Individuals taking anti-hypertensive
• Individuals with dyslipidemia on medication
• Females in peri-menopausal state (Irregular menstrual period in last 6 months).
• Females on Hormone Replacement Therapy
• Individuals with a history of or complications from inflammatory conditions.
• Use of another investigational product within 3 months of the screening visit
• Individuals with a history of or complications from malignant tumors
• History of any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
• Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine dependence.
• High-risk drinking as defined by consumption of 4 or more alcohol containing beverages on any day or 8 or more alcohol containing beverages per week for women and 5 or more alcohol containing beverages on any day or 15 or more alcohol containing beverages per week for men.
• Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
• Any condition that could, in the opinion of the investigator, preclude the individual's ability to successfully and safely complete the study or that may confound study outcomes.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

35 participants in 3 patient groups, including a placebo group

Dolichos biflorus (Horsegram) seed extract

Active Comparator group

Description:

1 capsule twice a day (Before breakfast \& dinner)

Treatment:

Dietary Supplement: Dolichos biflorus (Horsegram) seed extract

Carica papaya leaves extract

Active Comparator group

Description:

1 capsule twice a day (Before breakfast \& dinner)

Treatment:

Dietary Supplement: Carica papaya leaves extract

Placebo (MCC)

Placebo Comparator group

Description:

1 capsule twice a day (Before breakfast \& dinner)

Treatment:

Dietary Supplement: Placebo (MCC)